What is PsiThera?
PsiThera is at the forefront of biotechnology innovation, leveraging advanced computational intelligence and a deep understanding of biologically relevant protein states to engineer novel oral therapeutics. The company's core competency lies in its ability to discover and optimize drugs for immune and inflammatory conditions, a field where injectable treatments have long been the standard. By combining biophysics, computational modeling, and mechanistic biology, PsiThera's expert drug hunters are identifying new therapeutic avenues and developing optimized drug candidates. The company's pipeline is advancing rapidly, with a strategic focus on high-value targets, beginning with the Tumor Necrosis Factor (TNF) superfamily.
How much funding has PsiThera raised?
PsiThera has raised a total of $47.5M across 1 funding round:
Series A
$47.5M
Series A (2025): $47.5M with participation from Roivant Sciences, Lightstone Ventures, Eurofarma, and Samsara BioCapital
Key Investors in PsiThera
Roivant Sciences
Roivant Sciences is a tech-enabled healthcare company focused on advancing promising drug candidates and innovative healthcare technologies, likely specializing in late-stage development and strategic partnerships within the biopharmaceutical sector.
Lightstone Ventures
Lightstone Ventures is a venture capital firm that supports founders developing cutting-edge science into new therapies and medical technologies, with a focus on providing capital and strategic insights to biotech and medtech leaders.
Eurofarma
Eurofarma, based in Santiago, Chile, operates within the healthcare sector, suggesting a strategic interest in pharmaceutical development and market expansion within Latin America or globally.
What's next for PsiThera?
The substantial enterprise-level funding and recent strategic investment position PsiThera for accelerated development and potential market entry. This capital infusion is expected to fuel the advancement of its drug pipeline, particularly its focus on the TNF superfamily, and further enhance its computational drug discovery platform. The company's ability to attract significant backing from established players in the life sciences sector indicates strong validation of its scientific approach and therapeutic potential. PsiThera is poised to disrupt the treatment landscape for immune and inflammatory diseases, offering a more convenient and potentially more effective alternative to existing injectable therapies.
See full PsiThera company page
